×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BGNE – beigene, ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BGNE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
06:00 am
bgne
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
Low
Report
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
11/14
12:02 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/13
01:46 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
11/13
12:22 am
bgne
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
Low
Report
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
11/12
06:00 am
bgne
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
Low
Report
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
11/6
06:01 am
bgne
BeiGene to Present at the Jefferies London Healthcare Conference
Low
Report
BeiGene to Present at the Jefferies London Healthcare Conference
11/5
09:10 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
11/5
09:05 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
06:00 am
BGNE
beigene, ltd. - american depositary shares
MISS
Report
-1.3%
beigene, ltd. - american depositary shares
8/7/2024
06:00 am
BGNE
beigene, ltd. - american depositary shares
BEAT
Report
2.7%
beigene, ltd. - american depositary shares
5/8/2024
06:00 am
BGNE
beigene, ltd. - american depositary shares
BEAT
Report
6.1%
beigene, ltd. - american depositary shares
2/26/2024
06:00 am
BGNE
beigene, ltd. - american depositary shares
BEAT
Report
2.0%
beigene, ltd. - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:06 am
bgne
Form 8-K BeiGene, Ltd. For: Nov 14
Low
Report
Form 8-K BeiGene, Ltd. For: Nov 14
11/12
09:33 am
bgne
Form 10-Q BeiGene, Ltd. For: Sep 30
Low
Report
Form 10-Q BeiGene, Ltd. For: Sep 30
11/12
09:32 am
bgne
Form 8-K BeiGene, Ltd. For: Nov 12
Low
Report
Form 8-K BeiGene, Ltd. For: Nov 12
10/28
06:06 am
bgne
Form 8-K BeiGene, Ltd. For: Oct 25
Low
Report
Form 8-K BeiGene, Ltd. For: Oct 25
10/10
05:48 pm
bgne
Form 4 BeiGene, Ltd. For: Oct 08 Filed by: OYLER JOHN
Low
Report
Form 4 BeiGene, Ltd. For: Oct 08 Filed by: OYLER JOHN
10/8
04:24 pm
bgne
Form 144 BeiGene, Ltd. Filed by: OYLER JOHN
Low
Report
Form 144 BeiGene, Ltd. Filed by: OYLER JOHN
10/8
04:24 pm
bgne
Form 144 BeiGene, Ltd. Filed by: OYLER JOHN
Low
Report
Form 144 BeiGene, Ltd. Filed by: OYLER JOHN
10/2
07:21 pm
bgne
Form 4 BeiGene, Ltd. For: Sep 30 Filed by: Sharp Shalini
Low
Report
Form 4 BeiGene, Ltd. For: Sep 30 Filed by: Sharp Shalini
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/31
Amgen to take 20.5% stake in BeiGene to expand in China [Reuters (UK)]
37.2%
5/9 Q1/2019 3/31/2019 EPS -2.810 ZacksConsensus -3.090 ActVsEst 0.280 - Beat 10.7%
5/14 Beigene Ltd (NASDAQ: BGNE) had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an "overweight" rating on the stock. 8.1%
4/13 BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis 6.6%
3/13 Beigene Ltd (NASDAQ: BGNE) was upgraded by analysts at Macquarie from an "underperform" rating to a "neutral" rating. 6.2%
10/16 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $170.00 price target on the stock. 5.5%
12/16 Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha] 4.5%
11/18 Form 4 BeiGene, Ltd. For: Nov 15 Filed by: Wu Xiaobin 4.0%
9/8 BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update 4.0%
9/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 4.0%
5/9 Q1/2019 3/31/2019 EPS -2.810 ZacksConsensus -3.090 ActVsEst 0.280 - Beat 10.7%
5/14 Beigene Ltd (NASDAQ: BGNE) had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an "overweight" rating on the stock. 8.1%
4/13 BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis 6.6%
3/13 Beigene Ltd (NASDAQ: BGNE) was upgraded by analysts at Macquarie from an "underperform" rating to a "neutral" rating. 6.2%
10/16 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $170.00 price target on the stock. 5.5%
12/16 Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha] 4.5%
11/18 Form 4 BeiGene, Ltd. For: Nov 15 Filed by: Wu Xiaobin 4.0%
9/8 BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update 4.0%
9/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 4.0%
TOP News Decliners
9/26
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019
-12.8%
4/30 Form 4 BeiGene, Ltd. For: Apr 29 Filed by: Huang Jane -8.3%
9/5 Form 4 BeiGene, Ltd. For: Sep 03 Filed by: Huang Jane -8.0%
6/5 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference -7.2%
6/14 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) -6.9%
9/9 BeiGene rebounds from bearish report-stoked selloff, up 8% [Seeking Alpha] -6.3%
12/16 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia -6.2%
4/29 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -5.8%
3/3 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $200.00 price target on the stock. -5.7%
3/25 BeiGene Announces Supply Update for ABRAXANE® in China -5.6%
4/30 Form 4 BeiGene, Ltd. For: Apr 29 Filed by: Huang Jane -8.3%
9/5 Form 4 BeiGene, Ltd. For: Sep 03 Filed by: Huang Jane -8.0%
6/5 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference -7.2%
6/14 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) -6.9%
9/9 BeiGene rebounds from bearish report-stoked selloff, up 8% [Seeking Alpha] -6.3%
12/16 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia -6.2%
4/29 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -5.8%
3/3 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $200.00 price target on the stock. -5.7%
3/25 BeiGene Announces Supply Update for ABRAXANE® in China -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: